Grifols began production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the first specific drug developed to combat COVID-19. Grifols is producing this potential anti-COVID-19 passive immune therapy as part of a collaboration agreement with the U.S. government, including the FDA, the National Institutes of Health (NIH) and the Biomedical Advanced Research Development Authority (BARDA), among other health...